Frontier mental health research: psychedelics & drug studies

Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.

6 papers

Ketamine Pharmacology: An Update (Pharmacodynamics and Molecular Aspects, Recent Findings)

G. Mion, Thierry Villevieille
CNS Neuroscience & Therapeutics Summary & key facts 2013 656 citations

Ketamine has been used as a safe anesthetic for more than 50 years and also works well for pain relief. The active form is S(+)-ketamine and it is mainly broken down into an active metabolite called norketamine. Ketamine blocks NMDA receptors in the brain, which helps explain its special effects…

Anesthesia and Neurotoxicity Research Anesthesia and Sedative Agents Treatment of Major Depression

7-Hydroxymitragynine Is an Active Metabolite of Mitragynine and a Key Mediator of Its Analgesic Effects

Andrew C. Kruegel, Rajendra Uprety, Steven G. Grinnell, Cory Langreck, Elizabeth A. Pekarskaya, Valerie Le Rouzic, et al.
ACS Central Science Summary & key facts 2019 200 citations

Researchers found that the main kratom alkaloid, mitragynine, is turned by liver enzymes into a much more active compound called 7-hydroxymitragynine (7‑OH). In lab tests and in mice, 7‑OH acts more strongly at the mu-opioid receptor and reaches brain levels that can explain most or all of the pain relief…

Alkaloids: synthesis and pharmacology Chemical synthesis and alkaloids Traditional and Medicinal Uses of Annonaceae

Treatment of Acute Opioid Withdrawal with Ibogaine

Kenneth Alper, Howard S. Lotsof, Geerte M. N. Frenken, D Luciano, Jan Bastiaans
American Journal on Addictions Summary & key facts 1999 195 citations

This report describes 33 open-label treatments with the alkaloid ibogaine given for acute heroin withdrawal in non-medical settings. In 25 of the 33 people, visible signs of opioid withdrawal stopped within 24 hours and stayed absent during 72 hours of observation. The authors note the results are from uncontrolled, non-clinical…

Forensic Toxicology and Drug Analysis Neurotransmitter Receptor Influence on Behavior Opioid Use Disorder Treatment

Safety of ibogaine administration in detoxification of opioid‐dependent individuals: a descriptive open‐label observational study

Thomas Knuijver, Arnt Schellekens, Maarten Belgers, Rogier Donders, Toon van Oosteren, Cornelis Kramers, et al.
Addiction Summary & key facts 2021 45 citations

A descriptive open-label observational study of ibogaine in people with opioid use disorder found the drug can produce clear but reversible heart and nervous-system side effects. Reported effects included QTc prolongation (a change in the heart’s electrical timing), slow heart rate (bradycardia), and severe problems with balance and coordination (ataxia).…

Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes Neurotransmitter Receptor Influence on Behavior Substance Abuse Treatment and Outcomes

Oxa-Iboga alkaloids lack cardiac risk and disrupt opioid use in animal models

Václav Havel, Andrew C. Kruegel, Benjamin Bechand, Scot McIntosh, Leia S. Stallings, Alana Hodges, et al.
Nature Communications Summary & key facts 2024 14 citations

Researchers made new versions of the psychedelic drug ibogaine, called oxa-iboga compounds, by changing part of the chemical structure. In lab tests on human heart cells these new compounds did not show the heart-rhythm risk that ibogaine can cause. In tests with male rats, a single dose or a short…

Alkaloids: synthesis and pharmacology Chemical synthesis and alkaloids Neurotransmitter Receptor Influence on Behavior Ibogaine

The pharmacokinetics and pharmacodynamics of ibogaine in opioid use disorder patients

Thomas Knuijver, Rob ter Heine, Arnt Schellekens, Paniz Heydari, Luc Lucas, Sjoerd Westra, et al.
Journal of Psychopharmacology Summary & key facts 2024 8 citations

In 14 people with opioid use disorder who each received a single 10 mg/kg dose of ibogaine, researchers measured blood levels of ibogaine and its metabolites over 24 hours and linked those levels to side effects. They found large differences between people in how fast ibogaine was cleared, and that…

Neurotransmitter Receptor Influence on Behavior Psychedelics and Drug Studies Treatment of Major Depression
Summaries and links are for general information and education only. They are not a substitute for reading the original publication or for professional medical, legal, or other advice. Always refer to the linked source for the full study.